Articles tagged with Pancreatic Cancer
Researchers from Rutgers Cancer Institute have identified specific microorganisms associated with inflammation and poor survival in pancreatic tumors. These microbial signatures can be used as new targets for earlier diagnosis or treatment of the fourth leading cause of cancer death.
Researchers developed a novel organoid model to study pancreatic cancer cells' growth and arrangement. The model provides insight into the three-dimensional structure of tumors, enabling tracking of individual growth stages, cell divisions, and gene expression patterns.
A new study found that the organization of different types of immune cells within pancreatic tumors is associated with patient outcomes. Immune cells called IL-10+ myelomonocytes tend to be located close to specific T cell types, which may affect cancer treatment responses.
Researchers at UNC Lineberger Comprehensive Cancer Center have found a way to overcome barriers limiting cancer immunotherapies. They discovered that activating the STING protein can increase regulatory B cells, which suppress anti-cancer immunity.
A new genetic test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, improving the accuracy of diagnoses compared to current guidelines. The test distinguishes between different types of cysts with higher accuracy than traditional forms of surveillance and current pancreatic cyst guidelines.
Researchers found that the quality and mix of collagen in pancreatic ductal adenocarcinoma tumors affects prognosis. Patients with tumors containing cleaved Collagen I experienced poor survival prospects, while those with non-cleaved Collagen I had better outcomes.
Cleveland researchers reveal a new strategy to prevent blood clots by targeting overactive neutrophils, reducing clotting risk while minimizing bleeding risk. The findings may be especially impactful for cancer patients who experience blood clot complications.
Researchers at Mayo Clinic Comprehensive Cancer Center have identified a gene marker that may lead to more effective precision treatment for pancreatic ductal adenocarcinoma. The protein METTL16 is correlated with accumulated DNA damage and suppresses DNA repair, suggesting it as a potential biomarker for PARPi treatment.
Researchers found that stress granules are abundant in obesity-related pancreatic cancer and blocking their formation stops cancer growth in animals. The study reveals a potential new direction for developing cancer therapy by targeting stress granule formation.
A new AI tool has been developed to detect pancreatic cancer on CT scans with high accuracy, achieving 90% sensitivity and 96% specificity. The tool's performance is comparable to that of radiologists, offering a promising supplement for early detection and improved treatment outcomes.
Researchers at California NanoSystems Institute developed a nanocarrier that delivers a combination therapy to pancreatic tumors using irinotecan and 3M-052, resulting in improved treatment outcomes and reduced side effects. The simultaneous delivery of the two drugs outperformed separate treatments in mouse models.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
Champalimaud Foundation researchers have developed a new biomarker, IgG-positive EVs, to assess treatment response in pancreatic cancer patients. These extracellular vesicles increase during disease progression and decrease in response to therapy, offering a more reliable tool for evaluating tumour status.
A UCSF-led team reveals that tumor immune microenvironments play a crucial role in the progression of pancreatic cysts to pancreatic cancer. The study suggests that therapies targeting regulatory T cells and myeloid-derived suppressor cells could inhibit malignant progression and treat high-risk disease.
Researchers at UVA have discovered the mechanism behind gene regulation during organ development, shedding light on how genetic material interacts with transcription factors to create different cell types. The study's findings could offer insights into the initiation of certain cancers and inspire new therapeutic development.
A study has revealed two key transition points in the development of pancreatic cancer, shedding light on treatment resistance and possible new therapies. The research provides insights into how normal cells become precancerous and cancerous, as well as a new strategy for checkpoint immunotherapy.
The University of Cincinnati is conducting a study on a potential new treatment for pancreatic cancer using SapC-DOPG, a nanotechnology drug delivery system. The treatment has shown promise in reducing tumor growth by 50-80% in animal models and aims to develop an effective immunotherapy treatment.
Researchers have identified a group of deregulated genes in pancreatic cancer that may serve as potential therapeutic targets. These long non-coding RNAs, when silenced, reduced tumor aggressiveness and characteristics such as proliferation and invasion.
A trial involving 1000 patients with Lynch syndrome found that a daily dose of resistant starch reduced cancers in other parts of the body by over half, particularly upper GI cancers. The effect persisted for 10 years after stopping the supplement.
Researchers discovered cancer cells produce a unique collagen that alters the tumor microbiome and promotes cancer progression. Loss of this collagen reduces cancer cell proliferation and boosts anti-tumor immune response, offering a potential therapeutic strategy.
Researchers at Cold Spring Harbor Laboratory have developed a rapid organoid screening test that can predict response to neoadjuvant chemotherapy in pancreatic cancer patients. This test may help optimize personalized treatment plans and improve patient outcomes.
Combination chemotherapy with FOLFIRINOX before surgery increased survival in patients with borderline resectable pancreatic cancer, outperforming FOLFIRINOX plus radiotherapy. The study demonstrated the effectiveness of neoadjuvant chemotherapy in improving outcomes for these patients.
Researchers used radiomics-based machine learning models to detect pancreatic cancer on prediagnostic CT scans, identifying it up to 386 days before clinical diagnosis. The AI model showed high accuracy and specificity, with a range of 94-98%, and was unaffected by image variations.
A new study found that most patients with pancreatic cancer diagnosed through regular screenings had early-stage disease, leading to long-term survival. The study suggests that surveillance programs can help detect precancerous conditions and cancers early, when they are most treatable.
A preclinical study by Cedars-Sinai Cancer and Johns Hopkins University has discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice. The treatment, which combines anti-PD-1 immunotherapy antibody, FAKi, and CXCR4, prevents cancer metastasis and bolsters the immune system.
Researchers have discovered a key protein regulating pancreatic cancer cell growth and spread, which can be manipulated to reverse the process. Boosting levels of GREM1 has been shown to turn back aggressive tumours, making them easier to treat.
Researchers found that suppressing an enzyme called MSRA, which fixes oxidative damage to proteins, sparks the metastatic spread of pancreatic cancer cells. The discovery suggests that similar switches may exist in other cancers and lays the groundwork for redox-based targeted therapies.
A study published in Molecular Cell has identified a protein, MSRA, whose level of expression acts as a molecular switch between primary cancer growth and metastasis in PDA cells. The researchers found that high levels of MSRA expression keep the growing cells as part of the primary tumor, while low levels trigger metastasis.
A recent scientific review suggests that the oral microbiome may hold key answers to pancreatic cancer development, diagnosis, and treatment. The study found a distinct association between oral microbiome patterns and pancreatic tumors, with certain disease-driving bacteria identified in both.
Researchers from Japan and the US share new technologies and blood biomarkers to detect pancreatic cancer and identify high-risk individuals. The findings aim to decrease cancer mortality rates by developing attractive new methods for early diagnosis.
A drug targeting IDH1 mutations in select cancers also inhibits wild-type form under certain conditions, making it a promising therapeutic option. Laboratory experiments and mouse models demonstrate the efficacy of Ivosidenib against various cancer types, including pancreatic, colorectal, ovarian, and lung cancer.
Researchers from China have developed a novel bioconjugate that can suppress the growth of K-Ras mutant pancreatic tumors. The conjugate, which targets folate receptors and macropinocytosis, was found to be highly cytotoxic and effective at suppressing tumor growth.
Researchers at Yale University have discovered a potentially effective treatment for advanced pancreatic neuroendocrine tumors, with a combination of capecitabine and temozolomide yielding longer progression-free survival rates and higher response rates than temozolomide alone.
Researchers found that combining chemotherapy with immunotherapy increased one-year survival rates for patients with advanced pancreatic cancer, with anti-PD-1/chemo regimen showing the highest response. The study identified key immune system biomarkers associated with better outcomes, offering new hope for precision oncology.
The new guidelines expand indication for screening to all with BRCA 1/2 gene variations, increasing chances of early detection and treatment. The guidelines also acknowledge potential downsides of screening, including false-positive results and encourage careful patient counseling.
A new study finds that cancer patients are at a greater risk of developing diabetes, particularly those with lung, pancreatic, breast, brain, urinary tract, or uterine cancers. The study also shows that cancer patients who develop diabetes die sooner than survivors without diabetes.
A study found that high fat diets and synthetic substances in unregulated athletic performance enhancers can activate a receptor accelerating the progression of pre-cancerous lesions to pancreatic cancer in mice. Limiting exposure to these substances may help prevent pancreatic cancer development.
Adding diffusion-weighted MRI to conventional MRI enhances the differentiation of locally recurrent tumor and post-surgical fibrosis in pancreatic ductal adenocarcinoma resection. The study found higher sensitivity with DWI, facilitating earlier detection of recurrences.
A study has found that patients with pancreatic ductal adenocarcinoma (PDAC) are six times more likely to have had gallstone disease within the year prior to diagnosis than non-cancer patients. This association suggests that gallstones could be a warning sign for this aggressive and deadly cancer.
Research suggests gallstone disease may be an early indicator of pancreatic cancer, with patients having gallstones nearly six times more likely to develop the disease. This association could lead to earlier diagnosis and treatment, potentially improving survival rates for pancreatic cancer patients.
Researchers at Oregon State University have discovered a promising approach to treating pancreatic cancer, which has a low survival rate. The study found that a liposomal prodrug outperformed traditional treatments in cancer cell cultures and animal models.
UTSW researchers have identified a subset of cancer-associated fibroblasts that can be targeted to enhance immunotherapy in pancreatic cancer patients. The study found that these cells, known as antigen-presenting cancer-associated fibroblasts (apCAFs), interact with immune cells by displaying proteins called antigens on their surface.
A new study from University of Gothenburg found that men with high childhood BMI are at an elevated risk of obesity-related cancer, even if their weight is normal in young adulthood. The study analyzed data from 6,565 men born between 1945 and 1961 and found a persistently increased risk of adult obesity-related cancer.
Canada's cancer rates are declining overall, but new cases and deaths are on the rise due to an aging population and growing numbers. Despite this, efforts in cancer prevention, screening, early detection, and treatment have led to improved survival rates for those diagnosed with cancer.
Researchers at Cedars-Sinai have developed an AI tool that accurately predicts pancreatic cancer patients based on CT scan images. Lowering blood cholesterol has also been shown to slow the growth of prostate cancer by enhancing immune cell action. Additionally, a new study found that an ultrasound probe plugged into a smartphone can b...
A new study indicates that artificial intelligence can accurately predict who will develop pancreatic cancer based on pre-diagnostic CT scan images. The AI tool was trained to analyze textural differences in the pancreas and achieved an accuracy rate of 86% in identifying those who would eventually develop the disease.
Researchers discovered that sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances cancer cell invasion. ST6Gal-I, an enzyme that adds sialic acid to EGFR, plays a key role in tumor progression and metastasis.
Researchers identified estrogen-related receptor gamma (ERR γ) as crucial for preventing pancreatic auto-digestion in mice. In humans, lower levels of ERR γ were found in cells affected by pancreatitis. These findings suggest new therapies regulating ERR γ activity could help prevent or treat these conditions.
The Lustgarten Foundation has awarded a $5 million grant to Break Through Cancer to target KRAS in pancreatic cancer. The Conquering KRAS in Pancreatic Cancer Team will integrate clinical and laboratory approaches to understand why patients respond to new therapies.
Researchers at the University of Oklahoma are testing a novel therapy that combines local laser ablation and immunostimulants to treat metastatic pancreatic cancer. The treatment aims to stimulate the immune system to fight cancer cells, with promising preliminary results in pre-clinical studies and clinical trials.
The Lustgarten Foundation has awarded Career Development Grants to Pingping Hou and Edwin Manuel to fund research on pancreas cancer. Their projects focus on immune cell populations and nutrient uptake by cancer cells, aiming to develop novel therapies.
Researchers at Columbia University are studying the effects of heavy ion radiation therapy on hard-to-treat cancers, aiming to improve treatment outcomes. The new linac booster will help scientists better understand how carbon ions work against cancer, potentially leading to more effective therapies.
An AI model developed by researchers identified a subset of individuals with a 25-fold risk of developing pancreatic cancer within three to 36 months. The model used sequence of medical diagnoses from patient records to predict risk, which was validated in two independent datasets.
Dr. Philip D. Greenberg has been elected as the American Association for Cancer Research President-Elect for 2022-2023. He will work to harness advances in cancer research and translate them for patient benefit, with a focus on addressing disparities in minority engagement.
Researchers found that pancreatic cancer cells trigger the breakdown of collagen proteins, which increases arginine levels and signals stellate cells to build fibrotic meshes around tumors. This process, known as desmoplasia, creates a dense environment that promotes aggressive growth and blocks access to therapies.
Researchers have discovered two distinct classes of cancer-associated fibroblasts that accumulate in the pancreatic tumor microenvironment and play opposing roles. The study suggests that targeting these unique cell populations may improve treatment outcomes for pancreatic cancer patients.
Dr. Tony Hunter's groundbreaking work on protein tyrosine phosphorylation has led to the development of targeted cancer therapies and a deeper understanding of cancer biology. His discovery has been recognized with numerous awards, solidifying his legacy in cancer research.
Scientists at Albert Einstein College of Medicine have developed a novel therapeutic strategy that uses bacteria to deliver tetanus toxin into pancreatic tumor cells, inducing an immune response and killing the cancer. The treatment has shown promise in reducing cancer metastases by 87% and increasing mouse lifespan by 40%.
A ketogenic diet has been shown to starve pancreatic cancer cells and enhance the effectiveness of a triple-drug therapy. The study, led by TGen, found that the diet reduced glucose levels in tumors and elevated ketone bodies, leading to increased stress on cancer cells.